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Summary 
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Tissue-resident lymphocytes play a key role in immune surveillance, but it remains unclear 
how these inherently stable cell populations respond to chronic inflammation. In the setting 
of celiac disease (CeD), where exposure to dietary antigen can be controlled, gluten-
induced inflammation triggered a profound depletion of naturally-occurring V+/V1+ 
intraepithelial lymphocytes (IELs) with innate cytolytic properties and specificity for the 
butyrophilin-like (BTNL) molecules BTNL3/BTNL8. Creation of a new niche with reduced 
expression of BTNL8 and loss of V+/V1+ IELs was accompanied by the expansion of 
gluten-sensitive, interferon--producing V1+ IELs bearing T cell receptors (TCRs) with a 
shared non-germline-encoded motif that failed to recognize BTNL3/BTNL8. Exclusion of 
dietary gluten restored BTNL8 expression but was insufficient to reconstitute the 
physiological V+/V1+ subset among TCR+ IELs. Collectively, these data show that 
chronic inflammation permanently reconfigures the tissue-resident TCR+ IEL 
compartment in CeD. 
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Introduction 
Tissue-resident lymphocytes have been investigated extensively under steady 
state conditions and during the induction of local memory populations in response to acute 
infections (Mueller and Mackay, 2016). In mice, the tissue-resident TCR+ CD8+ pool 
is highly stable and responds to secondary antigenic challenge via local proliferation of 
pre-existing memory cells (Beura et al., 2018; Park et al., 2018), which endure over time 
despite the accumulation of new tissue-resident populations driven by subsequent 
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infections (Park et al., 2018). However, it remains unclear if chronic inflammation can 
permanently reconfigure the tissue-resident T cell compartment. 
Intraepithelial lymphocytes (IELs) expressing  T cell receptors (TCRs) are tissue-
resident T cells that play a key role in immune surveillance via dynamic scanning of the 
intestinal epithelium (Hoytema van Konijnenburg et al., 2017). Murine TCR+ cells seed 
the intestine early in life, irrespective of microbial colonization or exposure to dietary 
antigen (Di Marco Barros et al., 2016), and persist in situ as naturally-occurring IELs 
(Cheroutre et al., 2011). Moreover, the peripheral and intraepithelial TCR+ 
compartments are largely non-overlapping as a consequence of distinct migratory 
characteristics, especially a lack of recirculating IELs (Chennupati et al., 2010; Sugahara 
et al., 1999). 
Celiac disease (CeD) is a gastrointestinal inflammatory disorder triggered and 
maintained by dietary exposure to gluten (Jabri and Sollid, 2009). Antigen exposure can 
therefore be controlled in vivo, providing a unique opportunity to study the dynamics of 
human tissue-resident T cells in the setting of chronic inflammation. Active disease is 
characterized histologically by villous atrophy and immunologically by expanded 
populations of IELs (Jabri and Sollid, 2009). Adherence to a gluten-free diet (GFD) leads 
to resolution of the villous abnormalities, together with a decrease in the frequencies of 
gluten-specific TCR+ CD4+ T cells in the lamina propria and cytolytic TCR+ CD8+ 
IELs, which are consequently implicated in the pathogenesis of CeD (Jabri and Sollid, 
2009). In contrast, TCR+ IEL expansions generally persist in situ, despite a lack of 
exposure to gluten (Kutlu et al., 1993). For this reason, tissue-resident TCR+ IELs are 
thought to regulate disease activity (Hayday, 2000), potentially by suppressing the influx 
of circulating T cells and/or by maintaining tissue integrity (Hayday et al., 2001), rather 
than participate actively in the pathogenesis of CeD (Kutlu et al., 1993). However, these 
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propositions remain speculative, pending a detailed functional evaluation of TCR+ IELs 
in patients with CeD. We set out to address this knowledge gap and more fundamentally 
to determine the effects of chronic inflammation on human tissue-resident TCR+ IELs. 
 
Results 
 
V1+ T cells displaying hallmarks of tissue-resident lymphocytes are permanently 
expanded in CeD 
In line with previous studies (Halstensen et al., 1989; Kutlu et al., 1993), we found 
higher frequencies (Figure 1A) and absolute numbers (Figure 1B) of V1+ IELs in patients 
with CeD relative to healthy controls (Table S1), irrespective of adherence to a GFD 
(Figure 1C). Moreover, V1+ T cells constituted a significantly higher fraction of all 
TCR+ IELs in patients with active CeD (Figure 1D). A majority of V1+ IELs in healthy 
controls and patients with CeD expressed markers of tissue residency, namely CD69 and 
CD103 (Mueller and Mackay, 2016) (Figure 1E). V1+ IELs also expressed low levels of 
CD45RA and CCR7, indicative of an effector memory (TEM) phenotype (Sallusto et al., 
1999), whereas the corresponding V1+ peripheral blood lymphocytes (PBLs) comprised 
a mixture of naïve and terminally differentiated effector (TEMRA) cells (Figure 1F). Expanded 
populations of V1+ IELs were therefore integrated as bone fide tissue-resident 
lymphocytes in patients with CeD. 
 
Innate-like V1+ IELs are lost in CeD 
TCR+ CD8+ IELs in patients with CeD typically express increased levels of 
NKG2D and activating CD94/NKG2A– NK receptors (Jabri and Sollid, 2009). We found no 
evidence of a similar phenotype among V1+ IELs from patients with active CeD (Figure 
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S1A and S1B). However, a vast majority of control V1+ IELs expressed the activating 
natural cytotoxicity receptors (NCRs) NKp46 and/or NKp44 (Figure 2A), irrespective of 
age (Figure 2B) and in situ expansion (Figure S1C). These observations suggested a 
definitive tissue-resident phenotype, reinforced by a lack of NCR expression on the 
surface of V1+ PBLs (Figure S1D). In contrast, V1+ IELs from patients with active or 
GFD-treated CeD rarely expressed NKp46 and almost exclusively lacked NKp44 (Fig. 2A). 
This disease-associated loss of NCR+ V1+ IELs was refractory to long-term treatment 
with a GFD, unlike the concomitant loss of NCR+ CD3– IELs, indicating a cell type-
restricted effect distinct from the generic microenvironmental perturbations induced by 
CeD (Figure 2A and Figure S1E). Moreover, V1+ IELs expressing NKp46 and NKp44 
were absent from the duodenum, the site of tissue destruction, but present in the colon of 
patients with GFD-treated CeD (Figure 2C). These results suggested that chronic 
inflammation precipitated an irretrievable and active site-specific loss of NK-like V1+ IELs 
in patients with CeD. 
To determine the functional relevance of these NCRs, we measured cellular 
degranulation ex vivo and in response to stimulation with IL-15, which is upregulated under 
inflammatory conditions and is known to promote NK-receptor-mediated cytolytic activity 
(Jabri and Abadie, 2015). Co-engagement of NKp46 and NKp44 in conjunction with TCR 
ligation significantly increased granule exocytosis among control V1+ IELs relative to 
TCR ligation alone (Figure 2D), but only after pre-stimulation with IL-15 (Figure 2D and 
Figure S1F). V1+ IELs from healthy controls also expressed high levels of the cytolytic 
molecule granzyme B (Figure S1G) and degranulated at significantly higher frequencies 
than V1+ IELs from patients with CeD (Figure 2E). These findings revealed that the 
healthy small intestine harbored a unique set of innate-like and potentially cytolytic 
V1+ IELs that were displaced in the setting of CeD. 
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Dietary gluten drives the emergence of interferon--producing V1+ IELs in CeD 
To examine the functional properties of V1+ IELs in more depth, we extended our 
analysis to cytokine production directly ex vivo. Control V1+ IELs produced very little 
interferon (IFN)- or tumor necrosis factor (TNF)- on a percent cell basis (Figure 3A). In 
contrast, approximately 50% of V1+ IELs from patients with active CeD produced IFN-, 
but not TNF- (Figure 3A). Significantly lower frequencies of IFN-+ V1+ IELs were 
detected in patients with GFD-treated CeD (Figure 3A). Irrespective of disease status, 
V1+ PBLs produced both IFN- and TNF-, and neither TCR+ CD8+ nor TCR+ 
CD4+ IELs displayed enhanced production of IFN- in patients with active CeD (Figure 
3A). A significant increase in IFN- production was also detected among V1+ IELs 
isolated from patients with GFD-treated CeD after gluten challenge relative to donor-
matched V1+ IELs isolated prior to gluten challenge, whereas no such chronological 
differences were observed in the corresponding TCR+ CD8+ or TCR+ CD4+ IEL 
compartments (Figure 3B). These data suggested a gluten-dependent and cell type-
restricted gain of IFN--producing function among V1+ IELs in patients with active CeD. 
 
The transcriptional program of V1+ IELs is permanently altered in CeD 
In further analyses, we performed ex vivo RNA sequencing (RNA-seq) to 
determine if naturally-occurring V1+ IELs, represented by the prevalent NKp46+ (NCR+) 
subset in healthy controls, were fundamentally distinct from disease-associated 
V1+ IELs, represented by the prevalent NKp46– (NCR–) subset in patients with CeD. A 
total of 645 genes exhibited differential expression between control NCR+ V1+ IELs and 
NCR– V1+ IELs from patients with active CeD (Figure S2A). Similar differences were 
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observed in comparisons between control NCR+ V1+ IELs and NCR– V1+ IELs from 
patients with GFD-treated CeD (Figure S2B). Moreover, this overarching dichotomy was 
confirmed using minimum spanning tree (MST) analysis (Xu et al., 2002), which showed 
that control NCR+ V1+ IELs formed distinct clusters relative to NCR– V1+ IELs from 
patients with active or GFD-treated CeD (Figure 4A). 
Targeted analysis of genes encoding archetypal NK receptors and cytolytic 
effector molecules (Table S2) (Meresse et al., 2006) confirmed the innate-like nature and 
cytolytic potential of control V1+ IELs (Figure 4B). In particular, GZMK, FCGR3A, and 
TYROBP were significantly overexpressed among control NCR+ V1+ IELs (Figure 4B). A 
similar analysis of genes encoding various cytokines, chemokines, and growth factors 
(Table S2) revealed that IFNG, CCL4, and IL10 were significantly overexpressed among 
NCR– V1+ IELs from patients with CeD (Figure 4C). Transcripts encoding IL-4, IL-9, IL-
13, and IL-17 were not detected. Moreover, control NCR+ V1+ IELs expressed 
significantly more AREG, which encodes a growth factor implicated in tissue repair (Zaiss 
et al., 2015), relative to NCR– V1+ IELs from patients with active CeD (Figure 4C). 
Analogous patterns were observed for other genes associated with tissue repair (Linehan 
et al., 2018) (Figure 4D and Table S2). Clear differences also emerged with respect to the 
expression of transcription factors associated with immune function (Table S2). For 
example, control NCR+ V1+ IELs specifically expressed GATA3 and IRF8, which have 
been implicated in the regulation of innate immunity (Adams et al., 2018; Zhu, 2017), 
whereas IRF1 (Kano et al., 2008) and RUNX1 (Wang et al., 2014) were selectively 
overexpressed among NCR– V1+ IELs from patients with active CeD (Figure 4E), 
consistent with ability of these cells to produce IFN- (Figure 3A). 
 To assess the relative impact of origin versus phenotype, we also compared NCR+ 
V1+ IELs from healthy controls with NCR+ V1+ IELs from patients with active CeD. The 
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latter were occasionally found in younger patients (Figure S2C), but lacked expression of 
NKp44, in contrast to control NCR+ V1+ IELs. Unbiased multidimensional scaling (MDS) 
analysis revealed that control NCR+ V1+ IELs formed a distinct subset, whereas NCR+ 
and NCR– V1+ IELs from patients with active CeD clustered together (Figure S2D). 
Accordingly, differences observed between control NCR+ V1+ IELs and NCR– V1+ IELs 
from patients with active CeD (Figure S2B) were mimicked between control NCR+ V1+ 
IELs and NCR+ V1+ IELs from patients with active CeD (Figure S2E). Transcriptional 
differences among V1+ IELs were therefore driven by disease state rather than NCR 
expression, irrespective of adherence to a GFD. 
In line with the functional and phenotypic data, these results demonstrated that 
V1+ IELs formed distinct subsets characterized by divergent gene expression programs 
in healthy controls and patients with CeD. 
 
The V1+ IEL TCR repertoire is permanently reshaped in CeD 
To determine if the switch from innate-like NCR+ V1+ IELs in the healthy state to 
IFN--producing NCR– V1+ IELs in CeD was associated with cellular turnover, we used 
an unbiased molecular approach to characterize all expressed TRG and TRD gene 
rearrangements in flow-sorted V1+ T cell populations isolated directly ex vivo from donor-
matched PBLs and IELs (Figure S3A–C, Table S3, and Table S4) (Davey et al., 2017; 
Quigley et al., 2011). Control V1+ IELs almost exclusively used the TRGV4 gene, unlike 
donor-matched V1+ PBLs (Figure 5A, Figure 5B, and Table S5A). No such preference 
was observed in patients with active or GFD-treated CeD (Figure 5A, Figure 5B, and Table 
S5A). Accordingly, TRGV4 gene transcripts were significantly enriched among control 
V1+ IELs relative to V1+ IELs from patients with active or GFD-treated CeD (Figure 5A, 
Figure 5B, and Table S5A). These results were corroborated in a separate cohort via RNA-
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seq analysis, which also showed that TRGV gene use was not related to NCR expression 
(Figure S3D). Moreover, control V1– IELs displayed a similarly extreme preference for 
the TRGV4 gene and expressed NCRs at frequencies equivalent to those observed 
among control V1+ IELs (Figure 5C and Figure S3E). In contrast, V1– IELs from patients 
with CeD displayed no obvious preference for a particular TRGV gene and lacked 
expression of NCRs, akin to V1+ IELs from patients with CeD (Figure 5C and Figure 
S3E). This disease-associated loss of TRGV4 gene transcripts occurred independently of 
human leukocyte antigen (HLA) class II alleles linked with CeD (Table S3). Of note no 
TRGJ gene bias was observed among groups or tissues, reflecting widespread use of the 
TRGJ1 gene (Figure S3F and Table S5B). Collectively, these data suggested that TRGV4 
gene rearrangements facilitated the selection of naturally-occurring TCR+ IELs, which 
were supplanted in patients with CeD. 
 
A molecular signature defines V1+ IEL expansions in active CeD 
Next, we sought evidence of antigen-driven clonal expansions within the 
remodeled V1+ IEL TCR repertoires in patients with CeD. A subset of patients with active 
CeD harbored low-diversity repertoires, which were not apparent in patients with GFD-
treated CeD (Figure S4A). These results suggested that gluten consumption stimulated 
the expansion of particular clonotypes in the V1+ IEL pool, at least in some patients with 
active CeD, whereas gluten withdrawal allowed diversification, potentially via a loss of 
antigenic drive and/or de novo recruitment of non-expanded V1+ IELs. 
To address this possibility, we tested for amino acid (AA) preferences among 
unique CDR3 sequences, with the aim of identifying V1+ TCR motifs associated with 
active CeD. No group-specific AA enrichments were detected to indicate a disease-
associated molecular signature (Figure S4B and Table S5C). Of note, TRDJ1 gene 
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transcripts predominated across study groups (Figure S4C). At the genetic level, 
preferential use of TRDD3 and, to a lesser extent, TRDD2 in the forward frame was 
observed across the CDR3 data set as a whole (Figure S4D), but there was no evidence 
for preferential use of a specific TRDD gene among V1+ IELs from patients with active 
CeD (Figure S4E). These data suggested that gluten-induced reshaping of the V1+ IEL 
repertoire was not associated with a clear CDR3 motif. In line with this interpretation, two 
previously described CDR3 motifs associated with gluten challenge, CxxxxxPxLGD 
(PxLGD) and CxxxxxxxxYWGI (YWGI) (Han et al., 2013), were distributed at low 
frequencies in the corresponding V1+ repertoires obtained from patients with active or 
GFD-treated CeD (Figure S4E). However, the fraction of V1+ IEL-derived CDR3 
sequences that incorporated no TRDD gene-encoded AAs was significantly higher in 
healthy controls relative to patients with CeD (Figure S4F and Table S5D), and the 
corresponding CDR3 sequences were significantly shorter in healthy controls relative to 
patients with CeD (Figure S4G). 
In contrast, a similar analysis of CDR3 sequences revealed that histidine (H) was 
significantly enriched in the V1+ IEL repertoires obtained from patients with active CeD 
relative to the corresponding repertoires obtained from healthy controls and patients with 
GFD-treated CeD (Figure 6A and Table S5E). This observation was supported by iceLogo 
motif analysis (Colaert et al., 2009), which revealed a significant enrichment for H adjacent 
to the J segment among CDR3 sequences obtained from patients with active CeD 
(Figure S4H). In addition, H was found adjacent to the TRGJ1-encoded J segment (H-J1 
motif) in four public CDR3 sequences, collectively shared across six patients with active 
CeD (Figure 6B and Table S6). It is notable that these H-J1 CDR3 sequences associated 
with various TRGV gene segments (Figure 6B and Table S6). This pattern of mosaicism 
hinted at a unique selection pressure focused on the somatically rearranged CDR3 loop 
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in patients with CeD. A significantly higher fraction of unique CDR3 sequences carried 
the H-J1 motif in the V1+ IEL repertoires obtained from patients with active CeD relative 
to the corresponding repertoires obtained from healthy controls and patients with GFD-
treated CeD (Figure 6C). More specifically, H-J1+ CDR3 sequences were present in 
seven patients with active CeD versus only two patients with GFD-treated CeD, 
irrespective of HLA-DQ2/DQ8 genotype (Figure S4I and Table S3). The most common 
V1+ IEL-derived CDR3 sequence detected in four patients with active CeD incorporated 
the H-J1 motif (Figure 6D and Figure 6E). In contrast, the associated V1– IEL repertoires 
in these patients did not exhibit H-J1+ expansions, highlighting the lineage specificity of 
this molecular signature (Figure 6F). The most common V1+ PBL-derived CDR3 
sequence detected in three patients with active CeD also incorporated the H-J1 motif 
(Figure 6D and Figure 6E). Accordingly, V1+ TCR repertoires incorporating a dominant 
H-J1+ CDR3 sequence were significantly enriched among patients with active CeD 
relative to healthy controls and patients with GFD-treated CeD, compared across PBLs 
and IELs (Figure 6E). 
Collectively, these observations indicated that gluten-induced reshaping of the 
V1+ IEL compartment in patients with active CeD was associated with preferential 
recruitment and/or expansion of clonotypes bearing the H-J1+ CDR3 motif, which in turn 
suggested that the underlying chronic inflammatory process incorporated a degree of 
TCR-mediated specificity for a putative ligand associated with CeD. 
 
V1+ IELs display hallmarks of TCR-mediated activation in patients with CeD 
The combined observations that V1+ IELs acquired the ability to produce IFN- in 
response to gluten challenge (Figure 3B) and preferentially incorporated clonotypes 
bearing a shared H-J1+ CDR3 motif in patients with active but not GFD-treated CeD 
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(Figure 6D and Figure 6E) suggested the possibility of in vivo activation via the TCR. 
Analysis of a set of genes associated with T cell activation and TCR signaling (Table S2) 
(Fabregat et al., 2018) showed that NCR– V1+ IELs from patients with active CeD 
significantly overexpressed transcripts associated with antigenic stimulation relative to 
control NCR+ V1+ IELs (Figure 6G). More specifically, MKI67, CTLA4, PDCD1, and a 
subset of genes encoding HLA class II molecules were significantly overexpressed among 
NCR– V1+ IELs from patients with active CeD relative to NCR+ V1+ IELs from healthy 
controls and NCR– V1+ IELs from patients with GFD-treated CeD (Figure 6G). Gluten 
withdrawal was therefore associated with curtailed activation and a corresponding lack of 
TCR-driven selection among NCR– V1+ IELs (Figure 6C and Figure S4A). Direct ex vivo 
analysis of the transcription factor Nur77, which indicates signaling via the TCR (Ashouri 
and Weiss, 2017), further supported a direct link between gluten exposure and the 
activation status of NCR– V1+ IELs (Figure 6H). Accordingly, these data provided 
evidence for gluten-driven immune responses mediated via the engagement of specific 
V1+ IEL TCRs in patients with active CeD. 
 
BTNL3/8-reactive V1+ IELs are permanently lost in CeD 
Recent studies have shown that butyrophilin (BTN) and butyrophilin-like (BTNL) 
molecules play a key role in  T cell biology (Di Marco Barros et al., 2016; Melandri et al., 
2018; Vantourout et al., 2018). In line with the notion that human colonic V4+ IELs may 
be selected under physiological conditions by BTNL molecules (Di Marco Barros et al., 
2016), the loss of TRGV4 gene transcripts among V1+ IELs from patients with CeD 
(Figure 5A) was associated with corresponding decreases in BTNL8 gene transcript 
(Figure 7A) and protein expression levels (Figure 7B). Moreover, gluten withdrawal failed 
to restore TRGV4 gene use among V1+ IELs, despite normalization of BTNL8 expression 
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(Figure 7A, Figure 7B, and Figure S5A). In addition, V1+ IELs from patients with active or 
GFD-treated CeD were not activated in the presence of BTNL3/8+ HEK293T cells (Figure 
7C and Figure S5B), but responded efficiently to generic stimulation via cross-linking of 
TCRs (Figure S5C). Similar results were obtained with V1– IELs from patients with CeD, 
which lacked expression of TRGV4, but not with control V1+ and V1– IELs, which 
displayed an extreme preference for TRGV4 and responded in the presence of BTNL3/8+ 
HEK293T cells (Figure 5C and Figure 7D). Importantly, BTNL3/8-reactive V1+ IELs were 
lost from the duodenum, but not the colon, in a patient with GFD-treated CeD (Figure 
S5D). This finding concurred with the site-specific depletion of NCR+ V1+ IELs (Figure 
2C). Collectively, these results suggested that the recovery of BTNL molecules after 
exclusion of dietary gluten was insufficient to reconstitute the niche favored by naturally-
occurring V+/V1+ IELs, potentially reflecting an absolute homeostatic requirement for 
sustained expression of BTNL3/8. 
In some cases, patients with active CeD harbored populations of V+/V1+ IELs, 
which tended to express TCRs that were enriched for the H-J1 motif (Figure 7E). As V+ 
T cells from healthy human colon have been shown to react with BTNL3/8 (Di Marco 
Barros et al., 2016; Melandri et al., 2018), we formally tested the ability of V+/V1+ IEL 
H-J1+ TCRs from patients with active CeD to recognize BTNL3/8. Two V4+/V1+ IEL 
TCRs from healthy controls triggered dose-dependent responses to BTNL3/8, as 
expected, whereas a V3+/V1+ IEL TCR from a patient with active CeD failed to recognize 
BTNL3/8 (Figure 7F, Figure S5E, and Figure S5F). Strikingly, a V4+/V1+ IEL H-J1+ TCR 
from a patient with active CeD also failed to recognize BTNL3/8 (Figure 7F, Figure S5E, 
and Figure S5F). This particular TCR was characterized by the presence of a long CDR3 
loop (22 AAs), whereas control V4+/V1+ IEL TCRs typically incorporated shorter CDR3 
loops (Figure S4F). Moreover, the control V4+/V1+ IEL TCR with the shortest CDR3 
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loop (12 AAs, TCR 95) displayed the strongest reactivity against BTNL3/8 (Figure 7F). 
These observations suggested that the inability of the V4+/V1+ IEL H-J1+ TCR from the 
patient with active CeD to recognize BTN3/8 was related to the presence of a long CDR3 
loop, consistent with a recent study in which a V4+/V1+ IEL H-J1+ TCR with a short 
CDR3 loop recognized BTNL3/8 (Melandri et al., 2018). It remains to be determined if 
the HJ-1 motif can impede V4+/V1+ TCR interactions with BTNL3/8. Of note, all 
expressed TCRs transduced a functional signal in the presence of CD3/CD28 beads 
(Figure S5G and S5H). Collectively, these results provided direct evidence to support the 
contention that gluten-induced inflammatory remodeling of the TCR+ IEL compartment 
in patients with CeD was associated with a loss of productive TCR-mediated interactions 
with BTNL3/8. 
 
Dynamic remodeling of the V1+ IEL compartment precedes tissue damage in CeD 
The V1+ IEL compartment underwent dynamic changes both during the chronic 
inflammatory process associated with active CeD and during the resolution phase 
associated with strict adherence to a GFD (Figure S6). However, it was still unclear 
whether these alterations were causally or reactively linked with tissue damage. To 
address this issue, we analyzed patients with potential CeD, defined as a state of CD4+ T 
cell-mediated intolerance to dietary gluten without histological evidence of villous atrophy 
(Husby et al., 2012). This heterogeneous group encompassed patients with various levels 
of V1+ IEL infiltration (Figure S7A), loss of BTNL8 gene transcripts (Figure S7B), loss of 
NCR+ V1+ IELs (Figure S7C), and loss of TRGV4 gene transcripts (Figure S7D). This 
heterogeneity was further exemplified by two patients with potential CeD, one of which 
exhibited an expansion of NCR+ V1+ IELs with conserved ex vivo reactivity against 
BTNL3/8, and the other of which harbored physiological numbers of V1+ IELs that lacked 
 16 
NCR expression and ex vivo reactivity against BTNL3/8 (Figure 7G). In conjunction with 
the presence of occasional V1+ IEL TCRs bearing the H-J1+ CDR3 motif in patients with 
potential CeD (Figure S7E), these observations suggested that the loss of naturally-
occurring innate-like V1+ IELs may precede tissue destruction and the emergence of 
adaptive features within the disease-associated V1+ IEL repertoire. 
 
Discussion 
Current paradigms stipulate that tissue-resident immunity is established and 
maintained by long-lived, anatomically compartmentalized populations of lymphocytes, 
which adapt via local homeostasis and proliferation to novel antigenic challenges without 
displacing pre-existing memory specificities (Beura et al., 2018; Mueller and Mackay, 
2016; Park et al., 2018). However, the impact of chronic inflammation on the tissue-
resident lymphocyte pool has not been defined in previous studies, in part due to a lack of 
suitable models. We addressed this knowledge gap by taking advantage of the fact that 
antigen exposure can be controlled in CeD, a complex T cell-mediated inflammatory 
disorder with an autoimmune component (Jabri and Sollid, 2009). 
In healthy controls, we found that the tissue-resident TCR+ IEL compartment was 
dominated by a unique subset of innate-like, semi-invariant V4+/V1+ and V4+/V1- IELs 
that recognized BTNL3/BTNL8, constitutively expressed NCRs, and persisted throughout 
life, exemplifying the longevity and stability required to maintain durable immunity at 
barrier sites under physiological conditions. Importantly, these V4+/V1+ IELs were ideally 
poised to maintain homeostasis in the local microenvironment, either by eliminating virus-
infected or malignant cells in response to innate signals, such as NCR ligands and IL-15, 
or by promoting tissue healing via the production of growth factors, such as amphiregulin 
(Zaiss et al., 2015). 
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In patients with CeD, the tissue-resident V1+ IEL compartment was profoundly 
altered, even after exclusion of the inciting antigen and resolution of the associated 
inflammation. The key changes included an irretrievable loss of innate-like V+/V1+ IELs 
and the emergence of gluten-sensitive IFN--producing V1+ IELs characterized by clonal 
expansions incorporating H-J1+ TCRs that lacked reactivity against BTNL3/BTNL8. These 
observations challenge the assumption that pre-existing tissue-resident V1+ IELs expand 
in CeD (Hayday et al., 2001). We therefore propose a multistep model, whereby naturally-
occurring V+/V1+ IELs expand in response to inflammation, triggered by the loss of 
tolerance to dietary gluten, allowing initial preservation of NCR expression and 
BTNL3/BTNL8 reactivity, as observed in some patients with potential CeD. The ongoing 
disease process then reaches a tipping point, as observed in a subset of patients with 
potential or active CeD, where the chronic loss of BTNL8 expression eventually leads to 
the loss of V+/V1+ IELs, which likely depend on this ligand for survival. Circulating 
TCR+ cells are then recruited into the vacant immunological space and subsequently 
acquire a tissue-resident phenotype in response to local signals. In line with this 
proposition, V1+ PBLs from several patients with active CeD expressed TCRs 
incorporating the H-J1+ CDR3 motif, indicative of priming by a locally induced ligand in 
gut-associated lymphoid tissue (Guy-Grand et al., 2013). Moreover, gluten withdrawal 
precipitated a contraction of H-J1+ TCRs among V1+ IELs, consistent with the in situ 
expression of an antigen-dependent ligand in patients with active CeD. It is important to 
note that NCR+ V1+ IELs were occasionally found in patients with active CeD. However, 
these cells aligned transcriptionally with disease-associated NCR– V1+ IELs rather than 
control NCR+ V1+ IELs, lacked expression of NKp44 and the TRGV4 gene, and were only 
found in children with CeD. Accordingly, NCR expression is likely regulated by site-specific 
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signals, which are retained to some extent in children with active CeD, selectively 
facilitating the expression of NKp46 on V1+ IELs. 
A previous study in mice showed that V7+ IELs (the mouse homolog of human 
V4+ IELs) could not be rescued if the expression of BTNL molecules was delayed beyond 
the neonatal period, during which these cells typically expand in situ (Di Marco Barros et 
al., 2016). In conjunction with our finding that innate-like V+/V1+ IELs failed to recover 
in patients with GFD-treated CeD, despite restoration of the mucosal architecture and 
BTNL8 expression, this observation suggests that tissue-resident TCR+ IELs are 
exquisitely sensitive to the presence of BTNL molecules in the intestinal epithelium. It 
therefore seems likely that the profound changes we observed in the tissue-resident 
compartment of patients with CeD were underpinned by a loss of BTNL molecules in the 
local microenvironment, although it remains to be determined how long this state of 
depletion needs to persist to trigger the irretrievable destruction of a fully established niche 
constituted by mature populations of V+/V1+ IELs. 
It has been proposed that TCR+ IELs act to limit the infiltration of systemic T cells 
in CeD (Hayday et al., 2001), without playing a direct role in disease pathogenesis 
(Hayday, 2000; Kutlu et al., 1993). Our data challenge this assumption. In particular, we 
found that V1+ IELs in patients with CeD expressed high levels of the chemoattractant 
CCL4 and adopted a Th1-like phenotype, characterized by expression of IRF1 and 
RUNX1 and the production of IFN-. Moreover, only V1+ IELs showed enhanced IFN- in 
response to gluten challenge, which is highly relevant in the context of a Th1-mediated 
disorder like CeD. Previous studies have shown that IFN- induces the upregulation of 
HLA-E on intestinal epithelial cells (Meresse et al., 2006) and further upregulates major 
histocompatibility complex (MHC) class I molecules (Früh and Yang, 1999), which in turn 
can contribute to the activation of TCR+ CD8+ IELs, the primary mediators of 
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intestinal epithelial cell destruction in CeD (Jabri and Sollid, 2009). On the flip side of this 
argument, V1+ IELs also expressed genes associated with the regulation of chronic 
inflammatory responses, such as IL-10, CTLA4, PDCD1, and ZNF683, in patients with 
CeD. However, the corresponding molecules can equally act as proxies of chronic 
inflammation, in line with a pathogenic role for IFN--producing V1+ IELs. For example, 
Th1 cells self-regulate via the production of IL-10 (O'Garra and Vieira, 2007; Saraiva et 
al., 2009), and gluten-specific CD4+ T cells can express both IFN- and IL-10 (Nilsen et 
al., 1995). 
In conclusion, we have shown that chronic site-specific inflammation permanently 
reconfigures the tissue-resident TCR+ IEL compartment in patients with CeD. A similar 
process of ‘immunological scarring’ may contribute to the pathogenesis of other intestinal 
immune disorders, such as ulcerative colitis, which is also characterized by decreased 
levels of BTNL8 in situ. Further studies are therefore required to establish the general 
applicability of our findings across disease states and to determine the impact of chronic 
inflammatory processes on the stability of adaptive immune cell populations. In 
anticipation of these complementary data, we speculate that the irretrievable loss of 
tissue-resident subsets with unique innate-like specificities and cytolytic properties may 
have long-term implications for the health of patients with CeD. 
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FIGURE LEGENDS 
 
Figure 1. V1+ IELs with hallmarks of tissue residency are permanently expanded in 
CeD 
(A) Frequency of V1+ cells among CD3+ lymphocytes. Right: box plots display first and 
third quartiles. ***p<0.001. One-way ANOVA with Tukey’s test for multiple comparisons. 
(B) Absolute numbers of V1+ IELs from 3–5 biopsies per donor. Box plot displays first 
and third quartiles ***p<0.001. One-way ANOVA with Tukey’s test for multiple 
comparisons. (C) Frequency of V1+ IELs among CD3+ lymphocytes versus the duration 
of treatment with a GFD. Linear regression. (D) Frequency of V1+ IELs among total 
TCR+ T cells. Bottom: cumulative distribution. Healthy controls: n = 99. Patients with 
active CeD: n = 62. Patients with GFD-treated CeD: n = 57. Kolmogorov-Smirnov test. (E) 
Frequency of CD69+/CD103+ cells among V1+ PBLs and IELs. Bottom: box plot displays 
first and third quartiles. (F) Fraction of cells defined as naïve, central memory (TCM), 
effector memory (TEM), or terminal effector (TEMRA) based on expression of CD45RA 
and CCR7. 
 
Figure 2. Innate-like V1+ IELs are lost in CeD 
(A) Frequency of IELs expressing NKp46 with or without NKp44. Right: box plots display 
first and third quartiles. ***p<0.001. One-way ANOVA with Tukey’s test for multiple 
comparisons. (B) Expression of NKp46 or NKp46/NKp44 on control V1+ IELs versus age. 
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(C) Expression of NKp46 and NKp44 on V1+ IELs from donor-matched duodenal and 
right colonic biopsies. (D) Expression of CD107a on IL-15-treated IELs after stimulation 
with plate-bound TCR ± NKp46. *p<0.05. Paired t-test. (E) Expression of CD107a on 
V1+ IELs after stimulation with phorbol myristate acetate and ionomycin. Right: box plot 
displays first and third quartiles. **p<0.01, ***p<0.001. One-way ANOVA with Tukey’s test 
for multiple comparisons. 
 
Figure 3. Dietary gluten drives the emergence of IFN--producing V1+ IELs in CeD 
(A) Expression of IFN- and TNF- in cells stimulated ex vivo with phorbol myristate 
acetate and ionomycin. *p<0.05, **p<0.01, ***p<0.001. One-way ANOVA with Tukey’s test 
for multiple comparisons. (B) Expression of IFN- and TNF- in cells from patients with 
GFD-treated CeD stimulated as in (A) before and after a six-week gluten challenge. 
Duration of GFD: 1.5 years, 4 years, 7 years, and 20.5 years. *p<0.05. Paired t-test.  
 
Figure 4. The transcriptional program of V1+ IELs is permanently altered in CeD 
(A) Transcriptional profiles of NCR+ V1+ IELs from healthy controls, NCR– V1+ IELs from 
patients with active CeD, and NCR– V1+ IELs from patients with GFD-treated CeD 
compared using minimum spanning tree analysis. (B) Differentially expressed genes from 
the NK module passing a false discovery rate <10% from any two-way contrast between 
the V1+ IEL populations in (A). Expression values were standardized (mean centered) on 
a per gene basis. (C) Genes from the cytokine module passing the criteria in (B). (D) 
Genes from the tissue healing module passing the criteria in (B).  (E) Genes from the 
transcription factor module passing the criteria in (B). 
 
Figure 5. The V1+ IEL TCR repertoire is permanently reshaped in CeD 
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(A) Proportion of unique CDR3 sequences using a particular TRGV gene among V1+ 
PBLs and IELs. White lines demarcate individual contributions. Healthy controls: PBLs, n 
= 7; IELs, n = 8. Patients with active CeD: PBLs, n = 8; IELs, n = 8. Patients with GFD-
treated CeD: PBLs, n = 5; IELs, n = 7. *p<0.05, **p<0.01, ***p<0.001. Firth’s penalized 
logistic regression and beta regression. See Table S5A. (B) Data in (A) summarized by 
individual. (C) Proportion of unique CDR3 sequences using a particular TRGV gene 
among V1– IELs summarized by individual.  
 
Figure 6. A molecular signature defines V1+ IEL expansions in active CeD 
(A) Proportion of unique CDR3 sequences using a particular amino acid (AA). White lines 
demarcate individual contributions. Donor numbers as in Figure 5A. ‡ denotes AAs with 
significant differences between two groups. Firth’s penalized logistic regression and beta 
regression. See Table S5E. (B) Overlapping CDR3 sequences incorporating the H-J1 
motif. (C) Frequency of unique H-J1+ CDR3 sequences. Box plots display first and third 
quartiles. **p<0.01. Kruskal-Wallis rank sum test with Dunn’s test for multiple 
comparisons. (D) Dominant H-J1+ CDR3 sequences among patients with active CeD. (E) 
Frequency of dominant H-J1+ CDR3 sequences. 0 denotes samples in which the 
dominant CDR3 sequence lacked H-J1. Kruskal-Wallis rank sum test with Dunn’s test for 
multiple comparisons. (F) Frequency of unique H-J1+ CDR3 sequences among V1+ and 
V1– IELs from patients with active CeD. (G) Genes from the TCR activation module 
passing the criteria described in Figure 4B. (H) Expression of Nur77 in V1+ IELs versus 
CD3. Right: box plot displays first and third quartiles. **p<0.01. One-way ANOVA with 
Tukey’s test for multiple comparisons. 
 
Figure 7. BTNL3/8-reactive V1+ IELs are lost in CeD. 
 28 
 
(A) Expression of BTNL3 and BTNL8 relative to GAPDH in small intestinal biopsies via 
qPCR. Box plots display first and third quartiles. **p<0.01, ***p<0.001. Kruskal-Wallis rank 
sum test with Dunn’s test for multiple comparisons. (B) Immunohistochemical analysis of 
BTNL8 expression in duodenal sections. (C) Downregulation of CD3 and V1 on the 
surface of IELs pre-gated for V1 expression after overnight incubation with HEK293T-
BTNL8+ or HEK293T-BTNL3/8+ cells. Gating was patient-specific based on the HEK293T-
BTNL8+ condition. Right: box plot displays first and third quartiles. *p<0.05, ***p<0.001. 
Kruskal-Wallis rank sum test with Dunn’s test for multiple comparisons. (D) 
Downregulation of CD3 on the surface of V1– IELs. Details and statistics as in (C). (E) 
Proportion of unique CDR3 sequences expressing TRGV4 gene transcripts. Circles 
highlighted in black for patients with active CeD denote cases where the dominant TRGV4 
transcript incorporated the H-J1 motif. Box plot displays first and third quartiles. (F) SKW3 
cells stably expressing clonal TCRs were cultured for 2 hr with varying numbers of 
untransduced HEK293T cells (HEK293T-UT) or HEK293T-BTNL3/8+ cells. Activation was 
assessed via the induction of intracellular Nur77 from 3–5 independent experiments per 
TCR. Error bars display SD. *p<0.05. Paired t-test (HEK293T-UT versus HEK293T-
BTNL3/8+). (G) Frequency of V1+ IELs (left), expression of NKp46 and NKp44 on V1+ 
IELs (middle), and expression of CD3 and V1 on IELs after overnight incubation with 
HEK293T-BTNL8+ or HEK293T-BTNL3/8+ cells (right) for two patients with potential CeD. 
 
SUPPLEMENTAL INFORMATION 
 
Figure S1. Innate-like V1+ IELs are lost in CeD, Related to Figure 2 
(A) Expression of NKG2D on V1+ PBLs and IELs. Box plots display first and third 
quartiles. (B) Expression of CD94 and NKG2A on V1+ PBLs and IELs. Box plots display 
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first and third quartiles. CD94+/NKG2A–, activating; CD94+/NKG2A+, inhibitory. *p<0.05, 
***p<0.001. One-way ANOVA with Tukey’s test for multiple comparisons. (C) Frequency 
of V1+ IELs expressing NKp46 among total CD3+ lymphocytes. The red box depicts 
individuals with V1+ IEL expansions of similar magnitude to those found in patients with 
CeD. (D) Expression of NKp46 and NKp44 on PBLs. Bottom: box plots display first and 
third quartiles.  (E) Frequency of V1+ IELs expressing NKp46 or NKp46/NKp44 versus 
the duration of treatment with a GFD. (F) Expression of CD107a on V1+ IELs after 
stimulation with plate-bound TCR ± NKp46 and NKp44. Bottom: data summary. 
*p<0.05. Paired t-test. (G) Expression of granzyme B among subsets of IELs. Bottom: box 
plot displays first and third quartiles.  
 
Figure S2. The transcriptional program of V1+ IELs is permanently altered in CeD, 
Related to Figure 4 
(A) Differentially expressed genes (DEGs) between NCR+ V1+ IELs from healthy controls 
and NCR– V1+ IELs from patients with active CeD. DEGs highlighted in blue were more 
highly expressed in NCR– V1+ IELs from patients with active CeD (FDR <5%), and DEGs 
highlighted in red were more highly expressed in NCR+ V1+ IELs from healthy controls 
(FDR <5%). (B) DEGs shown in (A) were used to correlate the magnitude of gene 
expression differences between NCR+ V1+ IELs from healthy controls and NCR– V1+ 
IELs from patients with active CeD (x-axis) versus the magnitude of gene expression 
differences between NCR+ V1+ IELs from healthy controls and NCR– V1+ IELs from 
patients with GFD-treated CeD (y-axis). Genes with log2FC values >0 were more highly 
expressed in NCR– V1+ IELs from patients with active or GFD-treated CeD relative to 
NCR+ V1+ IELs from healthy controls, and genes with log2FC values <0 were more highly 
expressed in NCR+ V1+ IELs from healthy controls relative to NCR– V1+ IELs from 
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patients with active or GFD-treated CeD. Top left: log2FC distribution for all genes in the 
dot plot summarized as a histogram for each comparison. Pearson correlation. (C) 
Frequency of V1+ IELs expressing NKp46 or NKp46/NKp44 versus age for patients with 
active CeD. The red box depicts individuals <16 years old with high frequencies of NKp46+ 
V1+ IELs. (D) Multidimensional scaling plot showing gene expression profile similarity 
among NCR+ V1+ IELs from healthy controls, NCR+ V1+ IELs from patients with active 
CeD, NCR– V1+ IELs from patients with active CeD, NCR+ V1+ IELs from patients with 
GFD-treated CeD, and NCR– V1+ IELs from patients with GFD-treated CeD. (E) DEGs 
shown in (A) were used to correlate the magnitude of gene expression differences 
between NCR+ V1+ IELs from healthy controls and NCR– V1+ IELs from patients with 
active CeD (x-axis) versus the magnitude of gene expression differences between NCR+ 
V1+ IELs from healthy controls and NCR+ V1+ IELs from patients with active CeD (y-
axis). Genes with log2FC values >0 were more highly expressed in NCR+ and NCR– V1+ 
IELs from patients with active CeD relative to NCR+ V1+ IELs from healthy controls, and 
genes with log2FC values <0 were more highly expressed in NCR+ V1+ IELs from healthy 
controls relative to NCR+ and NCR– V1+ IELs from patients with active CeD. Top left: 
log2FC distribution for all genes in the dot plot summarized as a histogram for each 
comparison. Pearson correlation. 
 
Figure S3. The TRGV4 gene-associated ‘gut signature’ is lost in CeD, Related to 
Figure 5 
(A) Gating strategy: live CD3+ TCR+ V1+ lymphocytes were flow-sorted for molecular 
analysis of expressed TCRs. (B) Number of clones per individual/tissue yielding 
productive sequences for TCR and TCR. (C) Number of unique CDR3 sequences per 
group/tissue for TCR and TCR. (D) Expression of TRGV genes in NCR+ V1+ IELs from 
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healthy controls (n = 8), NCR+ V1+ IELs from patients with active CeD (n = 9), NCR– V1+ 
IELs from patients with active CeD (n = 9), NCR+ V1+ IELs from patients with GFD-treated 
CeD (n = 3), and NCR– V1+ IELs from patients with GFD-treated CeD (n = 5). Germline 
transcripts were extracted from the RNA-seq data set. Expression values were 
standardized (mean centered) on a per gene basis. (E) Frequency of V1– IELs expressing 
NKp46 or NKp46/NK/p44. Box plot displays first and third quartiles. ***p<0.001. One-way 
ANOVA with Tukey’s test for multiple comparisons. (F) Proportion of unique CDR3 
sequences using a particular TRGJ gene summarized by individual. 
 
Figure S4. V1+ IELs express TCRs with longer CDR3 loops in CeD, Related to 
Figure 6 
(A) Shannon diversity indices summarized in violin plots for CDR3 and CDR3 
sequences. (B) Proportion of unique CDR3 sequences using a particular amino acid 
(AA). White lines demarcate individual contributions. Healthy controls: PBLs, n = 7; IELs, 
n = 8. Patients with active CeD: PBLs, n = 8; IELs, n = 8. Patients with GFD-treated CeD: 
PBLs, n = 5; IELs, n = 7. ‡ denotes amino acids with significant differences between two 
groups. Firth’s penalized logistic regression and beta regression. See Table S5C. (C) 
Proportion of unique CDR3 sequences using a particular TRDJ gene summarized by 
individual. (D) Statistical assignment of TRDD gene use for each unique CDR3 
sequence. Each candidate forward and reverse TRDD gene sequence (rows) was tested 
for a significant substring match to each unique CDR3 sequence (columns). Significant 
TRDD gene assignments (FDR <0.05) are shown in red; non-significant TRDD gene 
assignments (FDR >0.05) are shown in blue. (E) Frequency of unique CDR3 sequences 
incorporating a particular CDR3 motif summarized by individual. (F) Proportion of unique 
CDR3 sequences using a particular feature. Healthy controls: PBLs, n = 7; IELs, n = 8. 
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Patients with active CeD: PBLs, n = 8; IELs, n = 8. Patients with GFD-treated CeD: PBLs, 
n = 5; IELs, n = 7. *p<0.05, ***p<0.001. Firth’s penalized logistic regression and beta 
regression. See Table S5D. (G) Cumulative distribution for CDR3 length across groups. 
**p<0.01. Kolmogorov-Smirnov test. (H) Unique CDR3 sequences among V1+ IELs from 
patients with active CeD visualized using iceLogo for enrichment of non-germline-encoded 
amino acids relative to unique CDR3 sequences among V1+ IELs from healthy controls 
and patients with GFD-treated CeD. Position 14 is closest to the TRGJ gene-encoded 
segment. (I) Frequency of unique CDR3 sequences with an H-J1 motif summarized by 
individual. 
 
Figure S5. BTNL3/8-reactive V1+ IELs are lost in CeD, Related to Figure 7 
(A) Proportion of unique CDR3 sequences using the TRGV4 gene versus relative 
expression of BTNL3 and BTNL8 for patients with GFD-treated CeD. Linear regression. 
(B) Expression of BTNL3 (myc+) and BTNL8 (HA+) on untransduced (UT) HEK293T cells 
(left), HEK293T cells transduced with BTNL8-HA (middle), and HEK293T cells transduced 
with BTNL3-myc and BTNL8-HA (right). (C) Downregulation of CD3 and V1 on the 
surface of IELs pre-gated for V1 expression after stimulation for 2 hr with 1.5 g/mL of 
plate-bound purified CD3. (D) Downregulation of CD3 and V1 on the surface of IELs 
pre-gated for V1 expression after overnight incubation with HEK293T-BTNL8+ or 
HEK293T-BTNL3/8+ cells. (E) SKW3 cell lines stably expressing clonal TCRs were 
cultured overnight with HEK293T-UT (black), HEK293T-BTNL8+ (blue), or HEK293T-
BTNL3/8+ cells (red). Top: representative histogram overlays displaying surface 
expression of CD3 on SKW3 cells. Bottom: box plots show first and third quartiles (n = 3 
independent experiments). *p<0.05, **p<0.01. One-way ANOVA followed by Tukey’s test 
for multiple comparisons. (F) SKW3 cells stably expressing clonal TCRs were cultured for 
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2 hr with varying numbers of untransduced HEK293T cells (HEK293T-UT) or HEK293T-
BTNL3/8+ cells. Representative contour plots from a single experiment display expression 
of CD3 and Nur77. (G) Expression of CD3 on unstimulated (black) or CD3/CD28-
stimulated SKW3 cells (red) stably expressing the indicated TCRs. (H) Surface expression 
of CD3 and intracellular expression of Nur77 for the indicated SKW transductants cultured 
with HEK293T-UT cells (untreated) or stimulated with CD3/CD28 beads.  
 
Figure S6. The tissue-resident V1+ IEL compartment is permanently reshaped in 
CeD, Related to Figures 1–7 
(A) Top: V1+ IELs are expanded in patients with CeD and adopt a tissue-resident 
phenotype characterized by expression of CD69 and CD103. Mean frequency values are 
summarized by group/tissue. Middle/top: V1+ IELs expressing NKp46 are lost in CeD and 
replaced by IFN--producing V1+ IELs. Mean frequency values are summarized by 
group/tissue. Middle/bottom: V1+ IELs lose the TRGV4 gene-associated ‘gut signature’ 
in patients with CeD (data summarized by group/tissue). This loss is associated with the 
emergence of CDR3 sequences incorporating the H-J1 motif among V1+ IELs in patients 
with active CeD. These H-J1+ CDR3 sequences become less common after exclusion of 
dietary gluten. Bottom: BTNL8 expression is lost in patients with active CeD, and V1+ 
IELs no longer recognize BTNL3/8. Although BTNL8 expression levels recover on a strict 
GFD, BTNL3/8 reactivity is permanently lost among V1+ IELs. (B) V1+ IELs in the healthy 
state (black) express NKp46 and NKp44, as well as V4+/V1+ TCRs that recognize 
BTNL3/8. These activating NCRs allow healthy V1+ IELs to recognize and eliminate 
stressed, infected, or malignant IECs. In patients with CeD, decreased expression of 
BTNL3 and BTNL8 is accompanied by a loss of V4+/V1+ IELs, which are replaced by 
V1+ IELs (red) that produce IFN-in a gluten-dependent manner and express TCR 
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chains enriched for the H-J1+ CDR3 motif that fail to recognize BTNL3/8. These H-J1+ 
V1+ IELs contract after withdrawal of dietary gluten, but are not replaced by NCR+ 
V4+/V1+ IELs. Instead, V1+ IELs in patients with GFD-treated CeD are enriched for 
TCRs that fail to recognize BTNL3/8. Repertoire diversity also increases (purple color 
gradient), suggesting of a lack of selection pressure in the absence of gluten-induced 
inflammation. This model is consistent with a fundamental reshaping of the tissue-resident 
V1+ IEL compartment after the onset of CeD. 
 
Figure S7. Alterations to the V1+ IEL compartment precede tissue damage in CeD, 
Related to Figure 7 
(A) Frequency of V1+ cells among total CD3+ lymphocytes. Box plot displays first and 
third quartiles. ***p<0.001. One-way ANOVA with Tukey’s test for multiple comparisons. 
(B) Expression of BTNL3 and BTNL8 relative to GAPDH in small intestinal biopsies 
determined via qPCR. Box plots display first and third quartiles. *p<0.05, **p<0.01, 
***p<0.001. Kruskal-Wallis rank sum test with Dunn’s test for multiple comparisons. (C) 
Frequency of V1+ IELs expressing NKp46 with or without NKp44. Box plot displays first 
and third quartiles. **p<0.01. One-way ANOVA with Tukey’s test for multiple comparisons. 
(D) Proportion of unique CDR3 sequences using a particular TRGV gene among V1+ 
IELs. White lines demarcate individual contributions. (E) Frequency of unique CDR3 
sequences incorporating the H-J1 motif among V1+ IELs. Box plot displays first and third 
quartiles. **p<0.01. Kruskal-Wallis rank sum test with Dunn’s test for multiple 
comparisons. 
 
STAR METHODS 
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CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and 
will be fulfilled by the Lead Contact, Bana Jabri (bjabri@bsd.uchicago.edu). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Patients were classified into four groups for the purposes of this study. Control – symptoms 
of upper gastrointestinal tract disease, with no histological evidence of duodenal 
inflammation, no family history of CeD, and negative serology for TG2. Active – 
histological evidence of villous atrophy, with positive serology for TG2. GFD – established 
diagnosis of CeD, with no histological evidence of villous atrophy, and negative serology 
for TG2. Potential – no histological evidence of villous atrophy, with positive serology for 
TG2. Exclusion criteria included immunosuppressive medication and coincident 
diagnoses of Barrett’s esophagus, eosinophilic esophagitis, cancer, cirrhosis, or 
inflammatory bowel disease (IBD). In challenge experiments, patients with GFD-treated 
CeD consumed 6 g of gluten daily for six weeks. Duodenal biopsies were taken from 3–5 
distinct sites, together with 2–8 mL of venous blood, under protocol 12623B approved by 
the Chicago Biomedicine Institutional Review Board. 
 
METHOD DETAILS 
Lymphocyte isolation 
PBLs were isolated from whole blood via standard density gradient centrifugation. IELs 
were isolated from duodenal biopsies via mechanical disruption. Briefly, duodenal tissues 
were shaken at 250 rpm for 30 min at 37 °C in 7 mL of RPMI 1640 medium supplemented 
with 1% dialyzed fetal bovine serum (Biowest), 2 mM EDTA (Corning), and 1.5 mM MgCl2 
(Thermo Fisher Scientific). The procedure was repeated once with fresh medium to 
 36 
enhance cell recovery. Cells were harvested from the biopsy-free media via centrifugation 
and pooled for subsequent analyses. 
Flow cytometry 
The following directly conjugated antibodies were used to identify cell surface markers: 
V1 APC (REA173), V1 FITC (TS8.2), V2 PE (B6), V2 PerCP (B6), TCR 
BV421 (IP26), TCR PE (5A6.E9), TCR PE-Cy5 (5A6.E9), CD3 APC (UCHT1), 
CD3 APC-Cy7 (UCHT1), CD3 PE-Cy7 (UCHT1), CD3 V450 (UCHT1), CD4 APC 
(RPA-T4), CD4 BV786 (SK3), CD8a BUV496 (RPA-T8), CD8a BV510 (RPA-T8), 
CD8a BV650 (RPA-T8), CD45 BV711 (HI30), CD45RA BV510 (HI100), CD69 PE 
(FN50), CD69 PE-CF594 (FN50), CD103 BUV395 (Ber-ACT8), CD107a BUV395 
(H4A3), CCR7 PE-Cy7 (G043H7), NKp44 APC (p44-8), NKp44 PE (p44-8), NKp46 
BV605 (9E2), NKp46 PE (9E2), Nur77 PE (12.14), Myc-Tag  PE (9B11), and HA-
Tag Alexa Fluor 647 (6E2). For intracellular cytokine detection, cells were 
fixed/permeabilized using a BD Cytofix/Cytoperm Plus Fixation/Permeabilization Solution 
Kit (BD Biosciences) and stained with the following directly conjugated antibodies: IFN-
 APC (4S.B3) and TNF- PE-Cy7 (MAb11). Antibodies were purchased from BD 
Biosciences, BioLegend, eBioscience, or Thermo Fisher Scientific. Dead cells were 
excluded from the analysis using LIVE/DEAD Fixable Aqua or LIVE/DEAD Fixable Near-
IR (Thermo Fisher Scientific). All flow cytometry data were analyzed using FlowJo 
software version 10.2 (Tree Star). 
Transcriptome sequencing 
Full-length cDNA and sequencing libraries were generated using a modified version of the 
single-cell Smart-seq2 protocol (Picelli et al., 2014). Briefly, 50–100 NCR+ (NKp46+) or 
NCR– (NKp46–) V1+ IELs were sorted into a lysis buffer containing oligo-dT and dNTPs. 
Reverse transcription was performed after hybridization of oligo-dT to poly-A RNA. The 
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resulting cDNA was amplified over 18 thermocycles, purified using an AMPure XP Kit 
(Beckman Coulter), and quality controlled using a Bioanalyzer High Sensitivity DNA Kit 
(Agilent). A total of 0.25 ng of cDNA from each sample was tagmented, ligated with 
adapters (Nextera XT), amplified over 12 thermocycles, and quality controlled using a 
Bioanalyzer High Sensitivity DNA Kit (Agilent). Libraries were then pooled in equimolar 
amounts and sequenced on two lanes in duplicate using a HiSeq4000 System (Illumina). 
HLA genotyping 
DNA samples were genotyped using an ImmunoArray BeadChip (Illumina) with single 
nucleotide polymorphism (SNP) probes as described previously (Trynka et al., 2011). Data 
analysis was performed using PLINK v1.9. Five of the six HLA-tagging SNPs reported 
previously (Monsuur et al., 2008) were covered on the ImmunoArray BeadChip. Genotype 
call rates were higher than 95%. HLA-DQ was inferred from a combination of genotypes 
at these five SNPs. 
TCR sequencing 
Lymphocytes were stained for viability and surface expression of CD3, TCR, TCR, 
V1, and V2. Live V1+ T cells were then sorted directly into 100 L of RNAlater (Thermo 
Fisher Scientific) using a FACSAria III flow cytometer (BD Biosciences) according to the 
gating strategy presented in Figure S3A. Cell numbers and patient details are summarized 
in Table S3. All expressed TRG and TRD gene transcripts were amplified using an 
unbiased template-switch anchored RT-PCR (Davey et al., 2017; Quigley et al., 2011). 
Amplicons were subcloned, sampled, and sequenced as described previously (Price et 
al., 2005). Gene use was assigned using the ImMunoGeneTics (IMGT) nomenclature 
(Lefranc, 2003). 
TCR/NKR stimulation assay 
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Polystyrene flat-bottom 96-well plates (Corning) were coated overnight at 4 °C with one of 
the following antibody cocktails: mix A – 0.5 μg/mL TCR (B1, BioLegend), 1 μg/mL 
mouse IgG2a  (MOPC-173, BioLegend), and 1 μg/mL mouse IgG2b  (MPC-11, 
BioLegend); or mix B – 0.5 μg/mL TCR (B1, BioLegend), 1 μg/mL NKp44 (195314, 
R&D Systems), and 1 μg/mL NKp46 (253415, R&D Systems). Lymphocytes were 
isolated from whole biopsies either pre-treated or not pre-treated with 10 ng/mL 
recombinant human IL-15 (BioLegend) for 18 hr at 4 °C and plated at a density of 2 x 105 
cells per well (1 x 106 cells/mL) in RPMI 1640 medium supplemented with 10% human AB 
serum (Corning), 0.1% GolgiPlug (BD Biosciences), 0.1% GolgiStop (BD Biosciences), 
and 10 ng/mL recombinant human IL-15 (if pre-treated with recombinant human IL-15). 
Surface upregulation of CD107a was quantified via flow cytometry after incubation for 3 
hr at 37 °C.  
Phorbol myristate acetate/ionomycin stimulation assay 
Lymphocytes were suspended in RPMI 1640 medium supplemented with 10% human AB 
serum (Corning), 10 ng/mL phorbol myristate acetate (Sigma-Aldrich), 150 ng/mL 
ionomycin calcium salt (Sigma-Aldrich), 100 U/mL recombinant human IL-2 (NIH AIDS 
Reagent Program), 0.1% GolgiPlug (BD Biosciences), and 0.1% GolgiStop (BD 
Biosciences) and distributed at 2 x 105 cells per well (1 x 106 cells/mL) in polystyrene flat-
bottom 96-well plates (Corning). Surface expression of CD107a and intracellular cytokine 
production were quantified via flow cytometry after incubation for 3 hr at 37 °C. 
Quantitative RT-PCR 
Duodenal biopsies were collected in RNAlater RNA Stabilization Reagent (Qiagen). After 
incubation for 48 hr at 4 °C, excess solution was removed, and the biopsies were stored 
at –80 °C. On the day of processing, biopsy material was thawed, suspended in 500 μL 
of Buffer RLT (Qiagen) supplemented with 1% -mercaptoethanol (Sigma-Aldrich), and 
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homogenized in a Bullet Blender 24 (Next Advance) using a 1:1 mix of 0.5 mm and 1.0 
mm zirconium oxide beads (Next Advance). RNA was then isolated using an AllPrep 
DNA/RNA/Protein Mini Kit (Qiagen). cDNA was generated from 200 ng of total RNA using 
a GoScript Reverse Transcriptase Kit (Promega). Expression of the genes of interest was 
measured via quantitative RT-PCR using SYBR Advantage qPCR Premix (Clontech) on 
a Light Cycler 480 Instrument II (Roche). The following parameters were used for 
amplification: denaturation for 10 sec at 95 °C, annealing for 10 sec at 60 °C, and 
extension for 10 sec at 72 °C. Human primer sequences were as follows: GAPDH forward: 
5’-ATGGGGAAGGTGAAGGTCG-3’; GAPDH reverse: 5’-
GGGGTCATTGATGGCAACAATA-3’; BTNL3 forward: 5’- 
TCAGTTTCTACGAGCTGGTGTC-3’; BTNL3 reverse: 5’-CCAAGGCCTGGACAAACTT-
3’; BTNL8 forward: 5’-GCTCTCATGCTCAGTTTGGTT-3’; and BTNL8 reverse: 5’-
GTCTGGCCCAAACACCTG-3’. The BTNL3 and BTNL8 primers were described 
previously (Lebrero-Fernández et al., 2016). 
Generation of HEK293T cell lines expressing BTNL3 and BTNL8 
Synthetic DNA (Genscript) encoding full-length human BTNL8 alone or full-length human 
BTNL3 and BTNL8 separated by a P2A (Teschovirus A) ribosomal skip sequence was 
subcloned into pMIG (Holst et al., 2006) and used to make retroviral particles (Gras et al., 
2010; Holst et al., 2006). Retrovirally transduced (GFP+) HEK293T cells were flow-sorted 
based on expression of the N-terminal myc (EQKLISEEDL(GGS)) tag to identify BTNL3 
and the N-terminal HA (YPYDVPDYA(GSG)) tag to identify BTNL8. 
Generation of SKW3 cell lines expressing V1+ TCRs 
Flow-sorted V1+ IELs isolated from healthy controls and patients with GFD-treated CeD 
were stimulated in vitro for two weeks at a starting density of 3 cells per well with irradiated 
B-lymphoblastoid cell lines and heterologous PBLs in RPMI 1640 medium supplemented 
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with 300 U/mL recombinant human IL-2 (NIH AIDS Reagent Program), 1 μg/mL 
phytohemagglutinin (Calbiochem), and 10% human AB serum (Atlanta Biologicals). 
Paired TCR and TCR sequences were obtained from clonally expanded V1+ IELs. 
Clonal expansions containing the H-J1 motif were sufficiently large in two patients with 
active CeD to allow frequency-based pairing of TCR and TCR sequences obtained 
directly ex vivo from bulk populations of V1+ IELs. Representative V1+ TCRs were stably 
expressed via retroviral transduction of the TCRαβ-deficient T cell leukemia cell line SKW3 
(German Collection of Microorganisms and Cell Cultures) (Gras et al., 2010; Holst et al., 
2006). 
BTNL3/8 reactivity assay ex vivo 
Round-bottom 96-well plates were seeded overnight with 2 x 105 HEK293T-BTNL8+ or 
HEK293T-BTNL3/8+ cells per well to create a monolayer. IELs were isolated from whole 
biopsies pre-treated with 10 ng/mL recombinant human IL-15 (BioLegend) for 16 hr at 4 
°C and overlaid at 1 x 105 cells per well on top of the pre-plated HEK cell monolayer. Cells 
were co-cultured for 24 hr and analyzed via flow cytometry for surface downregulation of 
CD3 (UCHT1) and V1 (REA173). As a positive control, IELs were simulated for 2 hr with 
1.5 g/mL of plate-bound purified CD3 (UCHT1).  
BTNL3/8 reactivity assay in vitro 
For CD3 downregulation, round-bottom 96-well plates were seeded overnight with 2 x 105 
HEK293T-UT or HEK293T-BTNL3/8+ cells per well to create a monolayer, and 1 x 105 
TCR-SKW3 cells were then added to each well and incubated for 24 hr at 37 °C. For 
Nur77 induction, round-bottom 96-well plates were seeded overnight with 3.125 x 103, 
6.25 x 103, 1.25 x 104, or 2.5 x 105 HEK293T-UT or HEK293T-BTNL3/8+ cells per well to 
create a monolayer, and 1 x 105 TCR-SKW3 cells were then added to each well and 
incubated for 2 hr at 37 °C. Flow cytometry was used to measure surface downregulation 
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of CD3 (UCHT1) or intracellular induction of Nur77 (12.14). As a positive control, 1 x 105 
TCR-SKW3 cells were stimulated for 2 hr with 2.5 L of Dynabeads Human T-Activator 
CD3/CD28 for T Cell Expansion and Activation (Thermo Fisher Scientific). 
Immunohistochemistry 
Duodenal biopsies were preserved in formalin and embedded in paraffin. Sections were 
cut to a thickness of 5 µm and stained with Bond RX Automatic Stainer (Leica 
Biosystems). Slides were then dewaxed three times with xylene, ethanol, and water, 
treated for 20 min with Epitope Retrieval Solution II (Leica Biosystems), incubated for 5 
min with 0.5% casein to prevent non-specific binding, and stained for 1 hr with a 1:200 
dilution of BTNL8 (2187B, R&D Systems). Antigen-antibody binding was revealed using 
Bond Polymer Refine Detection (Leica Biosystems). Tissue sections were then blocked 
with peroxidase, stained with DAB, and counter-stained with hematoxylin. Images were 
acquired using a ScanScope XT microscope (Leica Biosystems). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Transcriptome analysis 
A total of 34 RNA-seq libraries were generated from flow-sorted V1+ IELs, including 8 
from healthy controls (8 NCR+), 18 from patients with active CeD (9 NCR+ and 9 NCR–), 
and 8 from patients with GFD-treated CeD (3 NCR+ and 5 NCR–). Adaptor sequences and 
low-quality score bases (Phred score < 20) were trimmed using Trim Galore (version 
0.4.4). The resulting reads were merged per sample and mapped to the human genome 
reference sequence (Ensembl GRCh38 release 87) using kallisto (version 0.43.0) (Bray 
et al., 2016). To account for differences in read counts at the tails of the distribution, 
samples were normalized using the weighted trimmed mean of M-values algorithm (TMM), 
as implemented in the R package edgeR (Robinson et al., 2010). Data were then log-
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transformed using the voom function in the limma package (Ritchie et al., 2015). Non-
coding and lowly-expressed genes with an average (across all samples) log2(CPM) lower 
than 0 were excluded from downstream analyses, leaving a total of 16,066 genes. Linear 
models that accounted for differences in age and sex were used to identify genes with 
expression levels that varied between NCR+ samples from healthy controls, NCR+/NCR– 
samples from patients with active CeD, and NCR+/NCR– samples from patients with GFD-
treated CeD, implemented using the lmFit function in the limma package (Ritchie et al., 
2015). 
General procedure for analysis of TCR characteristics 
Sequences were first annotated for TRGV/J or TRDV/J using the IMGT database and V-
QUEST tool (Brochet et al., 2008). Annotated CDR3 sequences were then imported into 
R for further analysis. All detected sequences were captured in the analysis, including 
potentially non-functional TRGV10 gene transcripts. Clonal distribution in each sample 
was assessed using the Shannon diversity index. Sequence characteristics (TRV, TRD, 
and TRJ gene usage, and AA composition) were tested for association with patient groups 
and tissues. For each potentially distinguishing sequence characteristic (TRV, TRD, and 
TRJ gene usage, and AA composition), enrichment was scored by overall occurrence per 
group and by trends in occurrence per individual. Results that weighted each unique 
sequence equally were found to be more robust to potentially non-representative sampling 
than results that weighted each unique sequence by clonal size. Unique sequences were 
therefore weighted equally throughout the analysis, and the most strongly enriched 
features were identified as those passing both group and individual tests. For overall group 
enrichment testing, each unique TCR sequence labeled with or without the characteristic 
under question was used as the response variable in Firth’s penalized logistic regression 
performed with the group label as the predictor (logistf R package). This method allowed 
nearly complete separation of each characteristic by the group label predictor. Linear 
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hypothesis testing on the resulting group coefficients was then used to estimate the 
significance of each group comparison (multcomp R package). To test if the occurrence 
of a characteristic per individual shifted consistently between groups, characteristic 
proportions were explicitly modeled using beta regression (Smithson and Verkuilen, 
2006). The proportion of unique TCR sequences with the characteristic under question 
was first calculated for each individual. These proportion values were then used as the 
response variable in beta regression performed with the group label as the predictor 
(betareg R package). Due to the common presence of 0.0 and 1.0 proportion values 
(completely absent or present characteristics, respectively), raw proportion values (p) 
were transformed using (𝑝 ∙ (𝑛 − 1) + 0.5)/𝑛 , where n is the sample size, to ensure 
modeled values fell within the open interval (0,1) required for beta regression modeling 
(Ferrari and Cribari-Neto, 2004). Linear hypothesis testing on beta distribution mean 
coefficients per group was then used to estimate the significance of each group 
comparison (car R package).  
Shannon diversity index 
For each sample, the Shannon diversity index was calculated as 𝐻 = −∑ 𝑝𝑖 ln 𝑝𝑖𝑛 , which 
provides a measure of repertoire diversity. To account for variations in the numbers of 
recovered CDR3 sequences, individual datasets were subsampled 100 times to 50 CDR3 
sequences. The median index was then used to represent the score for each sample 
(vegan R package). 
Analysis of TRGV and TRGJ gene usage 
As described above, logistic regression was used to test for enrichment of TRGV and 
TRGJ gene segments in each group and each tissue. Significantly enriched gene 
segments were then tested for enrichment at the individual level using beta regression. 
Analysis of CDR3 AAs 
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For each full-length CDR3 sequence, the longest substring of AAs from the V and J ends 
that matched the corresponding TRV and TRJ germline sequences was identified using 
reference data provided by the IMGT database (Lefranc, 2003). The remaining AAs were 
considered non-germline, irrespective of potential contributions from the TRDD segment. 
The absence or presence of each AA was first determined in each unique CDR3. As 
described above, logistic regression was then used to test for the enrichment of each AA 
in each group, and significantly enriched AAs were tested for enrichment at the individual 
level using beta regression. 
Analysis of TRDD gene usage 
To determine the likely contribution of TRDD genes to each TCR sequence, an empirical 
statistic was generated to distinguish true germline matches from potentially spurious 
matches arising from random nucleotide additions. For each possible TRDD gene-derived 
nucleotide sequence, the longest substring match was first identified in each candidate 
CDR3 sequence, and 100,000 random nucleotide strings weighted by the observed 
nucleotide composition among all non-germline sequences were generated for each 
possible CDR3 length. By collecting match length statistics between a TRDD sequence 
and these random sequence sets, empirical null distributions of match length were 
obtained for each TRDD gene in both the forward and reverse frames. In each of these 
distributions, each match length bin contained at least 10 positive occurrences, assuring 
sufficient sampling coverage. These calculations allowed us to estimate an empirical p-
value for an observed TRDD gene sequence match, representing the probability of 
obtaining a match of the observed length or longer by chance. To account for testing a 
TRDD gene sequence against every unique CDR3 sequence, the set of empirical p-values 
was corrected according to the Benjamini-Hochberg multiple testing procedure, which 
quantifies the false discovery rate (FDR). This procedure was applied independently to 
each of three possible TRDD genes across both the forward and reverse nucleotide 
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sequences. Significant TRDD gene use was assigned at FDR values <0.05. Sequences 
were further annotated for each TRDD gene to identify the active reading frame. As 
described above, logistic regression spanning all annotated unique CDR3s was used to 
test for enrichment of TRDD gene segments in each group. Significantly enriched gene 
segments were then tested for enrichment at the individual level using beta regression. 
Analysis of TRDD gene use, statistical testing, and sequence annotation were performed 
using custom code written in R. 
iceLogo motifs  
Non-germline-encoded CDR3 AA sequences were right-justified at the junction with the J 
segment and analyzed using the iceLogo java application (Maddelein et al., 2015). Unique 
V1+ IEL CDR3 sequences from healthy controls and patients with GFD-treated CeD were 
pooled to serve as a fixed position background/reference set of sequences for 
visualization of AA enrichment among V1+ IEL CDR3 sequences from patients with active 
CeD. 
 
DATA AND SOFTWARE AVAILABILITY 
RNA-sequencing data were submitted to the Gene Expression Omnibus under accession 
code GEO: GSE123649. 
 
Table S1 – Summary of key cohorts, Related to Figures 1–7 
Table S2 – Gene modules, Related to Figure 4 and Figure 6 
Table S3 – TCR sequencing cohort, Related to Figure 5 and Figure 6 
Table S4 – TCR sequencing data set, Related to Figure 5 and Figure 6 
Table S5 – TCR analysis statistics, Related to Figure 5 and Figure 6 
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Significant differences that pass both the group and individual level tests are highlighted 
in red. (A) TRGV gene enrichment statistics. (B) TRGJ gene enrichment statistics. (C) 
CDR3 amino acid enrichment statistics. (D) TRDD gene enrichment statistics. (E) 
CDR3 amino acid enrichment statistics. 
Table S6 – List of overlapping CDR3 sequences, Related to Figure 6 
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